Login / Signup

Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study.

Akarin HiransuthikulRena JanamnuaysookKanittha HimmadStephen J KerrNarukjaporn ThammajarukTippawan PankamKannapat PhanjaroenStephen MillsRavipa VannakitPraphan PhanuphakNittaya Phanuphaknull null
Published in: Journal of the International AIDS Society (2020)
Our study demonstrated lower blood plasma TFV exposure in the presence of FHT, suggesting that FHT may potentially affect PrEP efficacy among TGW; but E2 exposure was not affected by PrEP. Further studies are warranted to determine whether these reductions in TFV are clinically significant. Clinical Trial Number: NCT03620734.
Keyphrases
  • clinical trial
  • men who have sex with men
  • type diabetes
  • emergency department
  • randomized controlled trial
  • hiv testing
  • bone marrow
  • study protocol
  • skeletal muscle
  • open label
  • antiretroviral therapy